Verona Pharma plc
VRNA
$65.46
$0.681.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 21.26% | 39.35% | -174.62% | -82.52% | 3.78% |
| Total Depreciation and Amortization | -2.63% | -1.48% | 2.66% | 26.44% | 34.19% |
| Total Amortization of Deferred Charges | -32.18% | -- | -- | -- | -87.38% |
| Total Other Non-Cash Items | 292.41% | -124.32% | 777.11% | 37.34% | -43.92% |
| Change in Net Operating Assets | -37.50% | -185.28% | 74.45% | 5,764.52% | 102.86% |
| Cash from Operations | 53.98% | -266.36% | -25.66% | -30.84% | 18.27% |
| Capital Expenditure | -- | 100.00% | -81.25% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | -81.25% | -- | -- |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | 2,583.21% | -- | -100.00% | -- | -- |
| Repurchase of Common Stock | 30.60% | -317.04% | 58.80% | 23.74% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -104.70% | 27,039.84% | -2,933.33% | -- |
| Cash from Financing | 1,428.59% | -104.25% | 5,442.04% | -113.01% | 49,925.00% |
| Foreign Exchange rate Adjustments | -190.36% | 7,293.75% | 111.35% | -117.71% | 216.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 192.94% | -145.79% | 986.42% | -217.24% | 207.82% |